Skyrizi®

INN: risankizumab

Approved for use in:

Crohn’s Disease (moderate-severe)

Type/Class

Originator Biologic

Delivery Route

Intravenous infusion, then subcutaneous injection

Health Canada Approval

2019

Storage

Refrigerate between 2 and 8°C, do not freeze, keep in original carton to protect from light.

Use in Older Adults (65+)

May be used, please consult your doctor.

Pregnancy Indication

Effects not studied; contraception recommended during treatment and for at least 20 weeks after last dose.

Breastfeeding Indication

Effects not studied; please consult your doctor.

Pediatric Indication

Safety and efficacy not established.

Learn More

View the Skyrizi® product monograph.